Medical Pharmacology: Chapter 24: Vasoactive Peptide Pharmacology -- Module 5: CGRP Pharmacology and Migraine Preventive Therapeutics

Chapter 24: Vasoactive Peptide Pharmacology — Module 5: CGRP Pharmacology and Migraine Preventive Therapeutics

1. A 58-year-old man with a 15-year history of episodic migraine presents to his neurologist requesting a more effective acute treatment. He has been using sumatriptan 100 mg orally with good efficacy, but his cardiologist has now documented stable angina and reduced coronary artery flow reserve on stress testing, and has recommended discontinuing sumatriptan. The patient asks whether any acute migraine medications remain available to him. His neurologist plans to switch him to an oral gepant. Which of the following most accurately explains why gepants are appropriate for acute migraine in this patient while triptans are now contraindicated?

A) Gepants are appropriate because they selectively inhibit COX-2 in trigeminal neurons, reducing prostaglandin-mediated sensitization without any vascular effects, while triptans inhibit both COX-1 and COX-2 nonselectively in coronary endothelium, producing thromboxane A2-mediated platelet aggregation that is dangerous in patients with coronary artery disease
B) Gepants are appropriate because they are competitive antagonists at the CLR/RAMP1 CGRP receptor and produce no vasoconstriction of any kind — they block CGRP-mediated vasodilation without activating any vasoconstrictor receptor; triptans are 5-HT1B/1D agonists, and 5-HT1B receptor activation on vascular smooth muscle produces direct coronary and peripheral arterial vasoconstriction that creates ischemic risk in vessels with already-compromised perfusion reserve from coronary artery disease
C) Gepants are appropriate because they act exclusively within the trigeminal ganglion and do not enter the systemic circulation in meaningful concentrations, while triptans achieve high systemic plasma concentrations that expose coronary vessels to direct drug contact; the coronary risk of triptans is entirely a function of plasma concentration rather than receptor mechanism
D) Gepants are appropriate in coronary artery disease because they upregulate endothelial nitric oxide synthase (eNOS) in coronary vessels, producing compensatory vasodilation that offsets any vasoconstrictive tendency, while triptans downregulate eNOS through 5-HT1B receptor coupling to Gi, reducing basal nitric oxide production and predisposing to coronary vasospasm
E) Gepants are appropriate because they are metabolized by MAO-A in the liver rather than the coronary endothelium, preventing direct endothelial drug exposure, while triptans are metabolized by CYP2D6 in coronary endothelial cells, generating reactive metabolites that damage atheromatous plaques and precipitate plaque rupture in patients with established coronary artery disease

ANSWER: B

Rationale:

This question tests the fundamental pharmacological distinction between gepants and triptans with respect to cardiovascular safety. The gepants — ubrogepant, rimegepant, atogepant, and zavegepant — are competitive antagonists at the CLR/RAMP1 CGRP receptor and have no vasoconstrictor activity whatsoever: they block CGRP-mediated vasodilation without activating any vasoconstrictor receptor. Triptans (sumatriptan, rizatriptan, eletriptan, and others) are 5-HT1B/1D receptor agonists. Activation of 5-HT1B receptors on coronary and peripheral vascular smooth muscle produces direct arterial vasoconstriction. In a patient with stable angina and documented reduced coronary flow reserve, triptan-induced coronary vasoconstriction superimposed on already-compromised perfusion creates a risk of worsening myocardial ischemia. The prescribing information for all triptans lists ischemic heart disease, coronary artery vasospasm, and other significant cardiovascular disease as contraindications. Gepants carry no such contraindication and are specifically positioned as the preferred acute therapy for migraine patients with cardiovascular disease who are excluded from triptan use.

Option A: Option A is incorrect because gepants are CGRP receptor antagonists, not COX inhibitors; they have no activity at cyclooxygenase enzymes, and the mechanism of triptan contraindication in coronary artery disease is 5-HT1B-mediated vasoconstriction, not COX-mediated platelet aggregation.
Option C: Option C is incorrect because gepants do achieve systemic plasma concentrations after oral or intranasal administration — they are not confined to the trigeminal ganglion — and the mechanism of triptan cardiac risk is receptor-mediated (5-HT1B agonism producing vasoconstriction), not simply a function of plasma drug concentration reaching coronary vessels.
Option D: Option D is incorrect because gepants do not upregulate eNOS, and triptans do not downregulate eNOS through Gi coupling; this mechanism does not correspond to the established pharmacology of either drug class, and the cardiac contraindication of triptans is based on direct 5-HT1B-mediated smooth muscle vasoconstriction rather than nitric oxide signaling effects.
Option E: Option E is incorrect because sumatriptan is metabolized primarily by MAO-A in the liver, not by CYP2D6 in coronary endothelium; triptan metabolites do not cause direct plaque damage, and the contraindication in coronary artery disease is mechanistic (5-HT1B vasoconstriction), not metabolic.

2. A 35-year-old woman with episodic migraine has been using rimegepant (Nurtec ODT) 75 mg every other day for migraine prevention with good tolerability. She develops a dermatophyte nail infection and her dermatologist prescribes itraconazole 200 mg daily for 12 weeks. Itraconazole is a potent CYP3A4 inhibitor. Her neurologist reviews the combination. Which of the following most accurately describes the pharmacokinetic interaction and the appropriate management?

A) Itraconazole has no clinically significant interaction with rimegepant because rimegepant is eliminated primarily by renal tubular secretion via OAT1 rather than hepatic CYP3A4 metabolism; itraconazole's CYP3A4 inhibition does not affect OAT1-mediated renal clearance, so the rimegepant dose requires no adjustment during the itraconazole course
B) Itraconazole increases rimegepant plasma exposure by inhibiting intestinal and hepatic CYP3A4, but the interaction is clinically managed by extending the rimegepant dosing interval to once every 4 days rather than every other day, reducing cumulative weekly exposure while maintaining the therapeutic trough concentration required for preventive efficacy
C) Itraconazole decreases rimegepant plasma exposure by approximately 60 percent through competitive displacement of rimegepant from plasma protein binding sites; the appropriate response is to increase the rimegepant preventive dose to 150 mg every other day to compensate for the reduced free fraction available for receptor binding
D) Itraconazole is a potent CYP3A4 inhibitor; rimegepant is a CYP3A4 and P-glycoprotein substrate, and co-administration with a strong CYP3A4 inhibitor substantially increases rimegepant plasma exposure; concomitant use is not recommended — the neurologist should advise the patient to hold rimegepant for the duration of itraconazole treatment and resume after the antifungal course is complete
E) Itraconazole induces CYP3A4 through pregnane X receptor (PXR) activation, reducing rimegepant bioavailability by approximately 70 percent; the clinical consequence is inadequate migraine prevention during the antifungal course, requiring a temporary switch to an anti-CGRP monoclonal antibody that does not undergo CYP450 metabolism

ANSWER: D

Rationale:

Rimegepant is a substrate of both CYP3A4 and P-glycoprotein (P-gp). Its oral bioavailability of approximately 64 percent reflects these metabolic and transport pathways. Itraconazole is among the most potent CYP3A4 inhibitors in clinical use — it also inhibits P-gp — meaning that co-administration with rimegepant substantially increases rimegepant plasma exposure through both reduced CYP3A4-mediated first-pass metabolism and reduced P-gp efflux. The prescribing information for rimegepant specifies that co-administration with strong CYP3A4 inhibitors is not recommended. The appropriate clinical management is to hold rimegepant for the duration of the itraconazole course and resume the preventive regimen once the antifungal is complete. For the 12-week treatment period, the patient and her neurologist should discuss alternative migraine management strategies if breakthrough attacks occur.

Option A: Option A is incorrect because rimegepant is not eliminated by OAT1-mediated renal tubular secretion; it is a CYP3A4 and P-gp substrate subject to hepatic and intestinal metabolism, and itraconazole's potent CYP3A4 inhibition produces a clinically significant pharmacokinetic interaction.
Option B: Option B is incorrect because extending the rimegepant dosing interval to every 4 days is not the recommended dose adjustment strategy in the prescribing information; the recommendation is to avoid co-administration entirely with strong CYP3A4 inhibitors, not to modify the dosing interval as a mitigation strategy.
Option C: Option C is incorrect because itraconazole inhibits (not reduces) rimegepant exposure, and competitive plasma protein displacement is not the mechanism of this interaction; CYP3A4 inhibition raises rimegepant AUC and Cmax, requiring avoidance rather than dose escalation.
Option E: Option E is incorrect because itraconazole is a CYP3A4 inhibitor, not an inducer; PXR activation with enzyme induction is the mechanism of drugs such as rifampin and carbamazepine — itraconazole produces the opposite effect by blocking CYP3A4 and raising drug exposure.

3. A 44-year-old woman with chronic migraine is scheduled for her quarterly eptinezumab (Vyepti) infusion at the neurology infusion center. She arrives at her appointment reporting that she woke up that morning with a severe migraine attack, currently rated 8 out of 10 in intensity, with nausea but no vomiting. Her neurologist proceeds with the eptinezumab 300 mg intravenous infusion over 30 minutes. The patient asks whether receiving the infusion during an active attack will be helpful or whether she should reschedule. Which of the following most accurately describes the pharmacokinetic basis for proceeding with the infusion and the expected clinical benefit?

A) Proceeding is inadvisable because eptinezumab requires 3 to 7 days to reach peak plasma concentrations after each quarterly dose, identical to subcutaneous anti-CGRP antibodies; receiving the infusion during an active attack will not affect the current attack and the patient should be treated with an acute migraine medication and rescheduled when headache-free to ensure optimal absorption
B) Proceeding is appropriate because eptinezumab crosses the blood-brain barrier by FcRn-mediated transcytosis during the active migraine state, when blood-brain barrier permeability is transiently increased; the heightened CNS penetration during an attack allows eptinezumab to directly block CGRP receptors at the trigeminal nucleus caudalis and abort the current attack within 60 minutes of infusion completion
C) Proceeding is appropriate because eptinezumab at the 300 mg dose activates 5-HT1B receptors on dilated dural vessels at supratherapeutic concentrations, producing vasoconstriction that aborts the current attack; this vasoconstrictive effect is dose-dependent and is the reason the 300 mg dose is preferred over 100 mg in patients with severe active attacks
D) Proceeding is inadvisable because eptinezumab at peak plasma concentration competes with endogenous CGRP for CLR/RAMP1 binding sites, but during an active migraine attack CGRP is released at concentrations that overwhelm the antibody's binding capacity; the antibody will be consumed by the attack-phase CGRP surge and will provide no residual preventive protection for the remainder of the quarterly interval
E) Proceeding is appropriate and clinically advantageous; eptinezumab is administered intravenously and achieves immediate maximal plasma concentrations at the completion of the 30-minute infusion — with no absorption phase — producing peripheral CGRP blockade from the moment infusion ends; PROMISE-1 and PROMISE-2 trial data demonstrated statistically significant reduction in migraine on day 1 post-infusion, and receiving the quarterly dose during an active attack provides concurrent acute CGRP suppression alongside the preventive dose

ANSWER: E

Rationale:

Eptinezumab (Vyepti) is the only anti-CGRP monoclonal antibody administered intravenously, given as a 100 or 300 mg infusion over 30 minutes quarterly. Its defining pharmacokinetic advantage over the subcutaneous anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab) is the absence of an absorption phase: the IV route delivers the full dose directly to the systemic circulation, achieving immediate maximal plasma concentrations at infusion completion. This translates to immediate peripheral CGRP blockade at meningeal trigeminal terminals and the trigeminal ganglion — both sites outside the blood-brain barrier and accessible to circulating antibody. The PROMISE-1 (episodic migraine) and PROMISE-2 (chronic migraine) pivotal trials demonstrated statistically significant reductions in migraine on day 1 post-infusion, confirming that immediate peak exposure produces clinically meaningful early efficacy. For a patient arriving with an active migraine attack, proceeding with the scheduled infusion provides both concurrent suppression of the attack-phase CGRP signaling and initiation of the quarterly preventive period — a practical advantage specific to eptinezumab's IV route unavailable with subcutaneous agents requiring 3 to 7 days to peak.

Option A: Option A is incorrect because it falsely characterizes eptinezumab's pharmacokinetics as identical to subcutaneous antibodies; eptinezumab achieves immediate peak concentrations via the IV route rather than the 3 to 7 day Tmax of subcutaneous delivery — this distinction is the defining pharmacokinetic feature of eptinezumab and the reason proceeding during an active attack is clinically advantageous rather than futile.
Option B: Option B is incorrect because eptinezumab does not cross the blood-brain barrier by FcRn transcytosis during migraine-state increased permeability; no anti-CGRP monoclonal antibody achieves clinically meaningful CNS penetration, and the therapeutic mechanism is peripheral CGRP blockade at accessible sites outside the BBB, not central TNC receptor blockade.
Option C: Option C is incorrect because eptinezumab has no 5-HT1B receptor activity at any dose; it is a CGRP ligand-targeting antibody with no serotonergic pharmacology, and the distinction from triptans in lacking vasoconstrictor activity is a class-defining feature of all CGRP-targeted therapies.
Option D: Option D is incorrect because eptinezumab's IgG binding capacity is not overwhelmed by attack-phase CGRP concentrations; therapeutic anti-CGRP antibody doses are administered in nanomole quantities designed to provide substantial excess over physiological CGRP levels, and the antibody is not depleted by a single attack's CGRP release.

4. A 39-year-old woman with chronic migraine was started on erenumab (Aimovig) 140 mg subcutaneously monthly 3 months ago. At her follow-up visit she reports significant improvement in migraine frequency — down from 17 to 6 migraine days per month — but describes new-onset constipation beginning approximately 4 weeks after her first injection. She has no prior history of constipation and takes no other medications associated with this symptom. Her neurologist explains that erenumab has a somewhat higher constipation rate than the ligand-targeting anti-CGRP antibodies and discusses the pharmacological mechanism. Which of the following most accurately explains the mechanism underlying erenumab-associated constipation?

A) Erenumab blocks CLR/RAMP1 CGRP receptors in the enteric nervous system, where CGRP — including enteric beta-CGRP expressed in gut neurons — normally modulates gastrointestinal motility; receptor-level blockade by erenumab removes this tonic enteric CGRP signal more completely than ligand-targeting antibodies (which primarily capture circulating alpha-CGRP), resulting in reduced intestinal smooth muscle activity and constipation
B) Erenumab-associated constipation results from its IgG2 subclass engaging Fcγ receptors on submucosal mast cells in the colonic wall, triggering histamine and serotonin release that paradoxically inhibits rather than stimulates peristalsis; ligand-targeting antibodies using IgG1, IgG2a, or IgG4 subclasses do not engage the same colonic mast cell Fcγ receptor subtypes and therefore do not produce this effect
C) Erenumab causes constipation through off-target blockade of adrenomedullin receptors (CLR/RAMP2) in mesenteric ganglia; adrenomedullin normally promotes cholinergic enteric neuron firing through RAMP2-mediated Gs signaling, and erenumab's cross-reactivity with CLR at the RAMP2 interface reduces colonic cholinergic drive and slows transit
D) Erenumab-associated constipation is a dose-independent class effect of all anti-CGRP monoclonal antibodies occurring at equal frequency with erenumab, fremanezumab, galcanezumab, and eptinezumab; the constipation reflects systemic CGRP pathway blockade reducing splanchnic blood flow, which slows mucosal absorption of water from the colonic lumen and produces harder, less frequent stools
E) Erenumab produces constipation through direct inhibition of 5-HT4 receptors on colonic enterocytes; the CLR/RAMP1 complex shares a transmembrane structural homology with 5-HT4 receptors, and erenumab's extracellular binding domain cross-reacts with the 5-HT4 receptor at the ligand-binding interface, reducing serotonin-driven peristaltic reflex activation in the sigmoid colon

ANSWER: A

Rationale:

CGRP is expressed in the enteric nervous system — specifically, beta-CGRP (encoded by the CALCB gene) is the predominant isoform in enteric neurons, where CLR/RAMP1 receptors on enteric neurons and smooth muscle modulate intestinal motility and peristaltic reflexes. Erenumab targets the CLR/RAMP1 receptor and therefore blocks CGRP signaling from all sources that reach that receptor — including enteric beta-CGRP. The ligand-targeting antibodies (fremanezumab, galcanezumab, eptinezumab) were developed primarily against circulating alpha-CGRP; their capture of enteric beta-CGRP may be less complete than erenumab's receptor-level blockade, either because of differential isoform affinity or because local enteric CGRP concentrations create an environment where antibody capture is less thorough than receptor occupancy. The net result is that erenumab produces more complete enteric CGRP pathway inhibition, manifesting clinically as a higher constipation rate. For patients with significant constipation on erenumab, switching to a ligand-targeting antibody is a reasonable clinical option.

Option B: Option B is incorrect because erenumab's constipation rate is not attributed to IgG2-mediated colonic mast cell activation; this mechanism is not established for erenumab's gastrointestinal adverse effect profile, and the pharmacological explanation centers on enteric CGRP receptor blockade rather than Fcγ receptor-mast cell interactions.
Option C: Option C is incorrect because erenumab is a highly selective antibody targeting the CLR/RAMP1 interface and does not produce meaningful cross-reactivity with CLR/RAMP2 (adrenomedullin receptor); the epitope is specific to the assembled CLR/RAMP1 heterodimer and does not extend to CLR/RAMP2.
Option D: Option D is incorrect because constipation is not a class effect of equal frequency across all four anti-CGRP antibodies; it is specifically more common with erenumab than with the ligand-targeting agents, which is the pharmacologically meaningful clinical observation, and reduced splanchnic blood flow is not the established mechanism.
Option E: Option E is incorrect because CLR/RAMP1 and 5-HT4 receptors share no clinically meaningful structural homology that allows erenumab cross-reactivity, and serotonin receptor cross-reactivity has not been described for any anti-CGRP monoclonal antibody.

5. A 47-year-old woman with chronic migraine and a demanding travel schedule is being initiated on a preventive anti-CGRP monoclonal antibody. She has previously failed topiramate due to cognitive side effects and propranolol due to fatigue. After reviewing the options, she states that her primary barrier to injectable therapy has been the inconvenience of monthly appointments or self-injections, and she asks whether a less frequent dosing schedule exists. Her neurologist selects fremanezumab (Ajovy). Which of the following most accurately describes the dosing flexibility of fremanezumab and the clinical rationale for selecting the quarterly option?

A) Fremanezumab offers a quarterly dosing option at 225 mg subcutaneously every 3 months; this lower quarterly dose is appropriate for patients with episodic migraine only, as the full 675 mg monthly-equivalent dose is required for chronic migraine patients to maintain sufficient CGRP blockade through the third month of the dosing interval
B) Fremanezumab is available only in a monthly 225 mg subcutaneous formulation; the quarterly option described in early clinical trials was not approved because the 675 mg dose produced injection site reactions severe enough to limit tolerability, and monthly dosing remains the only FDA-approved schedule for this agent
C) Fremanezumab is approved for both monthly dosing (225 mg subcutaneously once monthly) and quarterly dosing (675 mg subcutaneously once every 3 months); the monthly and quarterly schedules produce equivalent annualized migraine prevention, and the quarterly option — which requires only 3 injections per year versus 12 — directly addresses this patient's stated barrier of injection frequency without sacrificing efficacy
D) Fremanezumab's quarterly option requires administration at a healthcare facility rather than self-injection because the 675 mg dose must be delivered via slow intravenous infusion to prevent the immunogenicity that results from subcutaneous delivery of high-dose IgG antibodies; the monthly 225 mg dose is the only self-administered subcutaneous option
E) Fremanezumab is approved for quarterly dosing at 675 mg, but clinical trial data showed the quarterly schedule produces approximately 25 percent lower annualized migraine day reduction compared to monthly dosing; patients choosing quarterly dosing should be informed that they accept reduced efficacy in exchange for the convenience of less frequent injections

ANSWER: C

Rationale:

Fremanezumab (Ajovy) is unique among the anti-CGRP monoclonal antibodies in offering two FDA-approved dosing schedules with equivalent annualized efficacy: 225 mg subcutaneously once monthly, or 675 mg subcutaneously once every 3 months (quarterly). The quarterly dose of 675 mg is equivalent to three consecutive monthly doses given as a single larger injection at the start of each 3-month interval. Clinical trial data from the HALO-EM (episodic migraine) and HALO-CM (chronic migraine) trials confirmed that both regimens achieve comparable total annual CGRP blockade with equivalent annualized reductions in monthly migraine days. The choice between monthly and quarterly dosing is entirely patient-driven: patients who find monthly injections burdensome — due to travel schedules, needle aversion, or logistical barriers — can select the quarterly option without sacrificing preventive efficacy. For this patient, whose primary barrier is injection frequency, the quarterly 675 mg schedule reduces injections from 12 per year to 3 per year and directly addresses her stated concern.

Option A: Option A is incorrect because the quarterly dose is 675 mg (not 225 mg), and both the monthly and quarterly schedules are approved for both episodic and chronic migraine without restriction by migraine subtype; the claim that quarterly dosing is restricted to episodic migraine is factually wrong.
Option B: Option B is incorrect because fremanezumab does hold an FDA approval for the quarterly 675 mg dosing schedule, and injection site reactions were not the reason for any dosing limitation; both the monthly and quarterly formulations are approved self-administered subcutaneous injections.
Option D: Option D is incorrect because the quarterly 675 mg dose is administered subcutaneously by self-injection — not by intravenous infusion — and high-dose subcutaneous IgG delivery does not require IV administration to prevent immunogenicity; the IV route is the defining feature of eptinezumab, not fremanezumab.
Option E: Option E is incorrect because clinical trial data demonstrated equivalent annualized efficacy between monthly and quarterly dosing; there is no established 25 percent efficacy reduction with quarterly dosing, and patients are not counseled to accept reduced efficacy with the quarterly schedule.

6. A 51-year-old woman with high-frequency episodic migraine was started on erenumab 140 mg subcutaneously monthly 6 months ago. Initial response was promising — monthly migraine days fell from 12 to 5 — but over the past 2 months her migraine frequency has returned to near-baseline (10 days per month) despite adherence confirmed by pharmacy refill records. She has no new medications, no significant life stressors, and no change in sleep. Her neurologist attributes the loss of response to pharmacodynamic escape from erenumab and considers switching to a different anti-CGRP monoclonal antibody. Which of the following most accurately describes the pharmacological rationale for switching from erenumab to a ligand-targeting anti-CGRP antibody after receptor-targeted therapy failure?

A) Switching from erenumab to a ligand-targeting antibody is pharmacologically futile because all anti-CGRP antibodies produce identical downstream inhibition of CLR/RAMP1-mediated cAMP generation; once the trigeminal system has developed pharmacodynamic escape from CGRP pathway blockade at the receptor level, it will be equally refractory to ligand-level blockade through the same final common pathway
B) Switching from erenumab to a ligand-targeting antibody (fremanezumab, galcanezumab, or eptinezumab) is supported by a distinct pharmacological rationale: erenumab's receptor-targeted mechanism can be escaped through upregulation of CLR/RAMP1 receptor expression, downstream signal amplification, or CGRP-independent vasodilatory compensation — mechanisms that a ligand-targeting antibody bypasses by reducing the CGRP signal upstream of the receptor; real-world data support responses to second-line anti-CGRP antibodies after first-line failure
C) Switching is not recommended because prior exposure to erenumab invariably generates neutralizing anti-drug antibodies that cross-react with the CGRP-binding domain of fremanezumab and galcanezumab; the structural similarity between erenumab's receptor-binding epitope and the ligand-binding domains of the anti-CGRP antibodies means that immunological memory from erenumab renders subsequent anti-CGRP antibodies pharmacologically inert
D) Switching from erenumab to fremanezumab is appropriate only if the patient's erenumab failure is confirmed to result from receptor downregulation rather than antibody neutralization; a serum erenumab neutralizing antibody titer must be obtained before switching, and if neutralizing antibodies are detected, all anti-CGRP antibodies are contraindicated and the patient must return to conventional oral preventives
E) Switching to a ligand-targeting antibody after erenumab failure will produce benefit only if the patient's escape from erenumab was caused specifically by CGRP receptor upregulation; if escape occurred through non-CGRP vasodilatory pathways (adrenomedullin, VIP, substance P), ligand-level CGRP blockade will also fail and a non-CGRP preventive such as topiramate or amitriptyline is the recommended next step

ANSWER: B

Rationale:

The receptor-versus-ligand mechanistic distinction among the four approved anti-CGRP monoclonal antibodies provides a clinically meaningful rationale for switching after failure of one approach. Erenumab blocks the CLR/RAMP1 CGRP receptor, while fremanezumab, galcanezumab, and eptinezumab block the CGRP ligand. The mechanisms by which the trigeminal system can escape receptor-level blockade include upregulation of CLR/RAMP1 receptor density (maintaining downstream signaling despite individual receptor occupancy), amplification of downstream cAMP/PKA signaling components, or compensation through CGRP-independent vasodilatory pathways. A ligand-targeting antibody that reduces the CGRP signal upstream of the receptor can circumvent some of these receptor-level escape mechanisms by ensuring that less CGRP reaches the receptor regardless of receptor density changes. Conversely, a patient whose escape from ligand blockade involves CGRP upregulation overwhelming antibody capture might respond to receptor blockade. Real-world clinical registry data support meaningful response rates to second-line anti-CGRP antibodies — including across the receptor/ligand mechanistic divide — after first-line failure, and current headache society guidance endorses sequential anti-CGRP antibody trials.

Option A: Option A is incorrect because receptor-level escape mechanisms differ from ligand-level blockade response: a trigeminal system that has upregulated CLR/RAMP1 receptors to escape erenumab's receptor occupancy may still respond to reduced CGRP ligand availability, meaning the final common pathway argument does not eliminate the pharmacological rationale for switching.
Option C: Option C is incorrect because neutralizing anti-drug antibodies against erenumab do not reliably cross-react with the structurally distinct ligand-targeting antibodies; erenumab targets the CLR/RAMP1 receptor interface, while fremanezumab and galcanezumab target the CGRP peptide — these are different molecular epitopes, and immunological cross-reactivity between them is not established as a clinical barrier to sequential antibody use.
Option D: Option D is incorrect because routine serum neutralizing antibody testing before switching anti-CGRP antibodies is not current clinical standard practice, and detection of anti-drug antibodies is not a contraindication to sequential use of mechanistically distinct anti-CGRP antibodies.
Option E: Option E is incorrect because clinical practice does not require mechanistic confirmation of the specific escape pathway before switching; the switch decision is made on clinical grounds (loss of response with adherence confirmed), and routing patients back to conventional oral preventives solely on the theoretical basis of non-CGRP compensatory pathways is not supported by current headache society guidance.

7. A 42-year-old man with episodic migraine has been taking atogepant (Qulipta) 30 mg once daily for migraine prevention with good efficacy, reducing his monthly migraine days from 10 to 3. He is newly diagnosed with pulmonary tuberculosis and is started on a standard four-drug regimen that includes rifampin 600 mg daily. His neurologist reviews the drug interaction. Rifampin is a potent CYP3A4 inducer that acts through the pregnane X receptor (PXR). Which of the following most accurately describes the expected pharmacokinetic interaction and the appropriate clinical management?

A) Rifampin inhibits P-glycoprotein efflux transporters in the intestinal wall, trapping atogepant in enterocytes and reducing systemic absorption; the appropriate management is to administer atogepant 2 hours before rifampin to allow complete intestinal absorption before P-gp induction reaches maximal effect
B) Rifampin has no clinically significant interaction with atogepant because atogepant is eliminated by renal tubular secretion as unchanged drug; CYP3A4 induction by rifampin does not affect renal tubular transporters, so no dose adjustment is required during the tuberculosis treatment course
C) Rifampin inhibits CYP3A4 competitively by binding to the heme iron of the enzyme, doubling atogepant plasma exposure; the appropriate management is to reduce the atogepant dose to 10 mg once daily while rifampin is co-administered to avoid dose-dependent adverse effects
D) Rifampin substantially increases atogepant plasma clearance through CYP3A4 induction but the interaction is clinically insignificant because atogepant's preventive mechanism requires only threshold CGRP receptor occupancy, which is maintained even at 50 percent reduced plasma exposure; no dose adjustment is needed and the patient can continue 30 mg daily throughout the tuberculosis treatment course
E) Rifampin is a potent CYP3A4 inducer that substantially reduces atogepant plasma exposure by increasing its metabolic clearance; the prescribing information for atogepant specifies that the combination with strong CYP3A4 inducers should be avoided, or if unavoidable, the 60 mg once daily dose should be used to compensate for the reduced atogepant exposure — the current 30 mg dose will produce subtherapeutic plasma concentrations and loss of preventive efficacy during rifampin co-administration

ANSWER: E

Rationale:

Atogepant is a CYP3A4 substrate with an oral bioavailability of approximately 44 percent. Rifampin is among the most potent CYP3A4 inducers in clinical use, activating the pregnane X receptor (PXR) to upregulate CYP3A4 enzyme expression in both the intestinal wall and the liver. CYP3A4 induction by rifampin dramatically increases the first-pass and systemic metabolic clearance of CYP3A4 substrates, substantially reducing plasma AUC and Cmax. For atogepant, this means that the 30 mg once-daily preventive dose will produce subtherapeutic plasma concentrations during rifampin co-administration, leading to loss of migraine prevention. The atogepant prescribing information specifies that co-administration with strong CYP3A4 inducers should be avoided; if the combination is clinically necessary, the 60 mg once-daily dose is recommended to compensate for the reduced exposure. Given that rifampin is a cornerstone of tuberculosis treatment and cannot be readily substituted, the most appropriate management is to escalate the atogepant dose to 60 mg daily for the duration of rifampin co-administration, with close monitoring for efficacy.

Option A: Option A is incorrect because rifampin's relevant interaction mechanism with atogepant is CYP3A4 induction (not P-gp inhibition), and the effect of rifampin on P-gp is induction (not inhibition); timing of atogepant administration relative to rifampin does not circumvent CYP3A4 induction because enzyme induction is a transcriptional effect that takes days to reach maximum effect and persists around the clock regardless of dosing timing.
Option B: Option B is incorrect because atogepant is not eliminated by renal tubular secretion as unchanged drug; it is a CYP3A4 substrate requiring hepatic metabolism, and rifampin's CYP3A4 induction substantially reduces atogepant plasma exposure with direct clinical consequences for migraine prevention.
Option C: Option C is incorrect because rifampin is a CYP3A4 inducer, not an inhibitor; it does not bind to heme iron competitively — that mechanism describes reversible competitive inhibition, which is the mechanism of drugs like fluconazole; rifampin's induction mechanism involves PXR-mediated upregulation of CYP3A4 gene transcription, and the clinical consequence is reduced (not increased) atogepant exposure.
Option D: Option D is incorrect because the pharmacokinetic interaction between rifampin and atogepant is clinically significant — threshold CGRP receptor occupancy theory does not exempt CYP3A4 substrates from clinically meaningful induction interactions, and loss of preventive efficacy at substantially reduced plasma concentrations is a recognized clinical risk requiring dose adjustment per prescribing information.

8. A 38-year-old woman presents to a headache clinic with daily headache for the past 4 months. She has a background of episodic migraine that has progressively worsened over the past year. Chart review reveals she has been using sumatriptan on 14 to 16 days per month for the past 6 months. Her neurologist diagnoses medication overuse headache (MOH) superimposed on transformed migraine and counsels the patient on the need to reduce triptan frequency. The patient asks whether she can substitute a different acute migraine medication without the same MOH risk while she withdraws from sumatriptan overuse. Which of the following most accurately describes gepants' MOH risk profile and their role in managing this patient?

A) Gepants carry the same MOH risk as triptans and cannot substitute for sumatriptan during MOH withdrawal; both drug classes target the CGRP pathway and produce identical central sensitization with overuse, and substituting one for the other merely transfers the MOH mechanism without reducing the risk of headache chronification
B) Gepants are appropriate substitutes only if used no more than 3 days per month during the triptan withdrawal period; exceeding this threshold during MOH withdrawal produces a gepant-specific MOH syndrome characterized by dopaminergic rebound headache that is more difficult to treat than triptan-related MOH and requires inpatient detoxification
C) Gepants cannot be used during triptan MOH withdrawal because their competitive antagonism at CLR/RAMP1 produces a CGRP rebound syndrome — characterized by supraphysiological CGRP release — when used on consecutive days; this rebound worsens the central sensitization driving MOH and should be avoided until the patient has been triptan-free for at least 3 months
D) Gepants appear to have substantially lower MOH risk than triptans based on available clinical and post-marketing data; rimegepant used every other day for prevention does not produce MOH even with concurrent acute use, and gepants can serve as an MOH-safe bridge during triptan withdrawal — allowing the patient to treat breakthrough attacks without the MOH risk that sumatriptan carries at high use frequency
E) Gepants are superior MOH-safe alternatives only when combined with a concurrent anti-CGRP monoclonal antibody; gepant monotherapy at frequencies exceeding 10 days per month still produces MOH in approximately 30 percent of patients within 3 months, but the preventive antibody suppresses the central sensitization that would otherwise drive chronification, making the combination safe at any acute gepant use frequency

ANSWER: D

Rationale:

Medication overuse headache (MOH) occurs when acute migraine medications are used on more than 10 to 15 days per month for more than 3 months, producing chronification through central sensitization mechanisms. Triptans carry a well-established MOH risk at more than 10 treatment days per month — this patient's 14 to 16 days of sumatriptan use per month significantly exceeds this threshold and explains her transformation to daily headache. Gepants have a substantially lower MOH risk based on available data. The most compelling evidence is from rimegepant: used every other day for migraine prevention — a frequency that would clearly exceed MOH thresholds for triptans — rimegepant does not produce MOH, and this preventive use can occur concurrently with acute use without triggering chronification. Post-marketing surveillance for the gepant class as a whole has not established gepants as a cause of MOH in the way that triptans, opioids, and NSAIDs are. For this patient, transitioning to a gepant for acute treatment during triptan withdrawal allows her to treat breakthrough attacks without perpetuating the MOH cycle, while her headache specialist simultaneously addresses the underlying triptan overuse.

Option A: Option A is incorrect because gepants and triptans do not have identical MOH risk profiles; gepants have substantially lower MOH risk and are not contraindicated in patients who have developed triptan MOH — this distinction is a key clinical advantage of the gepant class.
Option B: Option B is incorrect because there is no established gepant-specific MOH syndrome, no dopaminergic rebound mechanism has been described for gepants, and a 3-day-per-month threshold for gepant use during MOH withdrawal is not supported by clinical evidence; gepants can be used more frequently than 3 days per month without triggering MOH.
Option C: Option C is incorrect because gepants do not produce a CGRP rebound syndrome with consecutive-day use; as competitive reversible antagonists they simply dissociate from the receptor as plasma levels decline, without driving supraphysiological CGRP release, and no gepant-induced CGRP rebound phenomenon has been described in clinical or post-marketing data.
Option E: Option E is incorrect because gepant monotherapy does not produce MOH in approximately 30 percent of patients at frequencies exceeding 10 days per month; this figure is fabricated and does not correspond to the available post-marketing data, which show gepants have substantially lower MOH risk without requiring concurrent monoclonal antibody co-administration.

9. A 31-year-old woman with episodic migraine describes attacks that escalate from mild prodromal symptoms to severe head pain within 20 minutes. She consistently experiences prominent nausea and vomiting within the first 30 minutes of headache onset, making it impossible to reliably swallow and retain oral medications. She has tried sumatriptan nasal spray with variable results. Her neurologist considers switching her to a gepant but recognizes that standard oral gepant formulations have limitations for her attack pattern. Which gepant formulation and pharmacokinetic profile is best suited to her clinical presentation, and why?

A) Zavegepant (Zavzpret) 10 mg intranasal spray is the most appropriate gepant for this patient; its intranasal route bypasses gastrointestinal absorption entirely, avoiding the vulnerability to nausea-induced gastroparesis that limits oral gepant reliability, and achieves peak plasma concentrations within approximately 30 minutes — providing faster systemic onset than oral gepants while retaining the class-defining absence of vasoconstriction that makes it safe regardless of cardiovascular status
B) Rimegepant (Nurtec ODT) 75 mg orally disintegrating tablet is the most appropriate gepant; it dissolves on the tongue and absorbs directly through the buccal mucosa into the systemic circulation, achieving peak plasma concentrations within 10 to 15 minutes — faster than subcutaneous triptans — and is specifically indicated for patients whose vomiting prevents conventional tablet swallowing
C) Ubrogepant (Ubrelvy) 100 mg is the most appropriate gepant because its low oral bioavailability of approximately 7 percent means that even partial absorption during vomiting provides sufficient systemic exposure; patients with gastroparesis and vomiting absorb a higher fraction of ubrogepant than healthy volunteers because prolonged gastric contact time compensates for reduced dissolution, maintaining therapeutic plasma concentrations
D) Atogepant (Qulipta) 60 mg taken at the first prodromal symptom before nausea develops is the most appropriate strategy; its 44 percent oral bioavailability ensures reliable absorption in the brief window before nausea onset, and the higher preventive dose taken acutely at prodrome provides both acute attack abortion and continuation of the preventive regimen without requiring an additional acute medication
E) Any oral gepant is equally appropriate for this patient because nausea and vomiting do not meaningfully affect gepant bioavailability; gepants are absorbed by active intestinal transporters (PEPT1 and OAT3) that maintain saturable uptake regardless of gastric motility, and the choice among oral gepants should be based on CYP3A4 interaction profile rather than route of administration or onset kinetics

ANSWER: A

Rationale:

Zavegepant (Zavzpret) is the only approved intranasal gepant, administered as a single 10 mg intranasal spray for acute migraine treatment. Its intranasal route of administration directly addresses both of this patient's clinical barriers. First, the intranasal route bypasses gastrointestinal absorption entirely, eliminating the vulnerability to nausea-induced gastroparesis that makes oral medication unreliable when vomiting begins within 30 minutes of headache onset; the nasal mucosa provides a direct vascular absorption pathway unaffected by gastric emptying rate or vomiting. Second, zavegepant achieves peak plasma concentrations within approximately 30 minutes of administration — substantially faster than oral gepants (Tmax approximately 1.5 to 2 hours) and comparable to subcutaneous triptans in onset profile. This rapid onset is specifically valuable for patients whose attacks escalate quickly. Like all gepants, zavegepant blocks CGRP-mediated vasodilation without activating any vasoconstrictor receptor, retaining the cardiovascular safety profile that distinguishes gepants from triptans.

Option B: Option B is incorrect because rimegepant ODT dissolves on the tongue but is not absorbed through the buccal mucosa into the systemic circulation; it is absorbed through the gastrointestinal tract after swallowing the dissolved material, with a Tmax of approximately 1.5 hours — not 10 to 15 minutes — and it is not equivalent to intravenous or subcutaneous administration in onset speed.
Option C: Option C is incorrect because reduced gastrointestinal motility from nausea and vomiting does not increase ubrogepant bioavailability; gastroparesis slows gastric emptying and reduces drug contact with intestinal absorptive surfaces, which would reduce rather than preserve ubrogepant absorption during severe nausea.
Option D: Option D is incorrect because atogepant is approved only for migraine prevention and holds no acute migraine treatment indication; the 60 mg dose is not approved for acute attack abortion, and prodromal administration of a preventive agent does not constitute acute rescue treatment.
Option E: Option E is incorrect because gepant absorption is not mediated by PEPT1 or OAT3 active transporters that are nausea-resistant; oral gepant bioavailability depends on passive and CYP-related processes subject to gastroparesis, and the clinical choice of intranasal over oral formulation is directly relevant and not reducible to CYP interaction profile.

10. A 55-year-old man with a 20-year history of episodic migraine suffered an ST-elevation myocardial infarction (STEMI) 8 weeks ago, treated with primary percutaneous coronary intervention (PCI) and dual antiplatelet therapy. He is referred to neurology for migraine management; his neurologist had been planning to start a monoclonal antibody for migraine prevention before the cardiac event. His cardiologist asks whether an anti-CGRP monoclonal antibody is appropriate to initiate at this time. Which of the following most accurately reflects current guidance on the use of anti-CGRP therapies in this clinical situation?

A) Anti-CGRP monoclonal antibodies are appropriate to initiate at this time because the patient's recent myocardial infarction was caused by atherosclerotic plaque rupture, not by CGRP-mediated vasospasm; since the antibodies produce no vasoconstriction, they pose no additional ischemic risk in a patient with established coronary stent patency confirmed by PCI
B) Anti-CGRP monoclonal antibodies are contraindicated permanently in any patient with a prior myocardial infarction because CGRP blockade eliminates the cardioprotective CGRP signaling that prevents infarct extension; even after full recovery, CGRP-targeted preventive therapy is considered too high-risk and patients with any prior MI must use only conventional oral preventives indefinitely
C) Current guidance recommends avoiding anti-CGRP therapies in patients with recent major cardiovascular events, including myocardial infarction, within approximately 3 to 6 months; the mechanistic concern is that CGRP serves as a coronary vasodilator and cardioprotective peptide during ischemia, and the pivotal antibody trials excluded patients with recent MI, creating a limited safety database in this population — the appropriate approach is to defer anti-CGRP initiation until the patient is beyond the high-risk recovery period and then reassess with cardiology input
D) Anti-CGRP monoclonal antibodies are safe to initiate at any time after PCI because coronary stent placement eliminates the anatomical substrate for CGRP blockade-related ischemia; once a coronary stenosis has been stented, CGRP-mediated vasodilation of that vessel segment is no longer physiologically relevant, removing the mechanistic basis for the cardiovascular concern
E) Anti-CGRP therapies are safe to initiate 4 weeks after myocardial infarction in patients who have undergone successful PCI with drug-eluting stents, as confirmed by current American College of Cardiology guidelines that specifically exempt PCI-treated STEMI patients from the cardiovascular caution language in anti-CGRP prescribing information; the headache specialist may proceed without cardiology co-sign

ANSWER: C

Rationale:

The cardiovascular safety concern surrounding CGRP-targeted therapy is mechanistically grounded in CGRP's physiological role as a coronary vasodilator and cardioprotective peptide. CGRP is released from perivascular cardiac sensory nerve terminals during ischemia, where it produces coronary vasodilation and exerts direct cardioprotective effects on cardiomyocytes through cAMP-mediated anti-apoptotic signaling. Preclinical studies demonstrated that CGRP receptor antagonism worsened myocardial infarct size and impaired ischemic preconditioning. Because of this mechanistic concern, all pivotal anti-CGRP antibody clinical trials excluded patients with recent myocardial infarction (typically within 3 to 6 months), stroke, unstable angina, or uncontrolled hypertension, creating a safety database that is deliberately limited in this population. Current American Headache Society guidance recommends avoiding anti-CGRP therapies in patients with recent major cardiovascular events — myocardial infarction, stroke, and unstable angina — within approximately 3 to 6 months, and exercising clinical judgment in patients with stable cardiovascular disease beyond that window. With this patient only 8 weeks post-STEMI, he falls within the high-risk exclusion period; the appropriate management is to defer anti-CGRP initiation, manage his migraine with conventional strategies in the interim, and reassess candidacy with cardiology input once he is beyond the 3 to 6 month recovery period.

Option A: Option A is incorrect because the cardiovascular safety concern with anti-CGRP therapy is not limited to vasospasm — the mechanistic concern is loss of CGRP-mediated cardioprotection during ischemia, which is relevant even after PCI-treated atherosclerotic MI; the absence of vasoconstriction from gepants and antibodies does not eliminate the cardioprotective CGRP signal concern during the vulnerable post-MI recovery period.
Option B: Option B is incorrect because anti-CGRP therapy is not permanently contraindicated in all patients with any prior MI; the guidance recommends a time-limited avoidance period of approximately 3 to 6 months after a major cardiovascular event, after which anti-CGRP therapy may be considered with appropriate clinical judgment and cardiology input.
Option D: Option D is incorrect because coronary stent placement does not eliminate the physiological relevance of CGRP-mediated coronary vasodilation; CGRP vasodilatory signaling acts on coronary smooth muscle throughout the coronary tree, not only in previously stenotic segments, and the cardioprotective anti-apoptotic effects of CGRP on cardiomyocytes are relevant across the entire myocardium regardless of stent placement.
Option E: Option E is incorrect because no ACC guideline specifically exempts PCI-treated STEMI patients from the cardiovascular caution language in anti-CGRP prescribing information, and 4 weeks post-MI does not meet the 3 to 6 month deferral period recommended in current headache society guidance; cardiology co-sign and shared decision-making are appropriate rather than proceeding independently.

11. A 46-year-old woman with high-frequency episodic migraine (13 days per month) is started on galcanezumab (Emgality) for prevention. Her neurologist administers a 240 mg loading dose as two simultaneous 120 mg subcutaneous injections at the first visit, followed by a plan for 120 mg once monthly. The patient asks why she needs a double dose at the first visit rather than simply starting with 120 mg monthly. Which of the following most accurately explains the pharmacokinetic rationale for the galcanezumab loading dose?

A) The 240 mg loading dose is required because galcanezumab's IgG4 subclass undergoes rapid Fab-arm exchange in vivo at the time of first injection, generating bispecific half-antibodies with reduced CGRP affinity; the doubled initial dose compensates for the 50 percent loss of functional binding capacity from Fab-arm exchange so that sufficient monospecific anti-CGRP antibody remains to achieve therapeutic CGRP blockade from the first month
B) The 240 mg loading dose rapidly saturates CGRP neutralizing capacity in the systemic circulation, allowing excess antibody to cross the blood-brain barrier and achieve immediate central trigeminal nucleus caudalis CGRP receptor blockade; the 120 mg maintenance dose is sufficient only for peripheral CGRP blockade and cannot achieve the CNS concentrations needed for full preventive efficacy without the initial saturation dose
C) The loading dose is required because galcanezumab binds plasma proteins (primarily albumin) with high affinity at concentrations below 120 mg; the initial 240 mg dose saturates albumin binding sites, freeing unbound drug to reach meningeal CGRP receptors, while subsequent monthly 120 mg doses maintain free drug concentrations above the therapeutic threshold without further albumin saturation
D) The 240 mg loading dose is necessary because galcanezumab's IgG4 subclass has a shorter half-life than IgG1 or IgG2 antibodies due to reduced FcRn binding affinity at acidic endosomal pH; the double first dose compensates for faster clearance so that therapeutic plasma concentrations are maintained through the first monthly interval until steady state is approached
E) The loading dose accelerates achievement of therapeutic plasma concentrations by compensating for the slow subcutaneous absorption kinetics of large IgG antibodies; subcutaneous antibodies have a Tmax of 3 to 7 days and reach steady-state only after multiple monthly doses — without a loading dose, the patient would have subtherapeutic galcanezumab concentrations for several months before accumulation reaches preventive levels; the 240 mg loading dose front-loads the antibody exposure to achieve near-therapeutic concentrations from the first dosing interval

ANSWER: E

Rationale:

The pharmacokinetic rationale for the galcanezumab loading dose follows directly from the general principles governing subcutaneous monoclonal antibody pharmacokinetics. Subcutaneous antibodies have a Tmax of approximately 3 to 7 days and a terminal half-life of approximately 27 to 31 days. Without a loading dose, monthly administration of 120 mg would result in gradual accumulation over several dosing intervals before reaching steady-state concentrations — a process that could take 3 to 5 months to achieve maximal preventive plasma levels. For a patient with 13 migraine days per month, waiting months for effective preventive concentrations to accumulate is clinically unacceptable. The 240 mg loading dose (administered as two simultaneous 120 mg injections) front-loads the antibody exposure: by giving twice the monthly maintenance dose at initiation, the antibody concentration in the first dosing interval approximates what would otherwise require months of accumulation to achieve, rapidly establishing meaningful CGRP blockade from early in the treatment course. This approach is analogous to the use of loading doses for other drugs with long half-lives where rapid achievement of therapeutic levels is clinically important.

Option A: Option A is incorrect because while galcanezumab does use the IgG4 subclass and IgG4 antibodies do undergo Fab-arm exchange in vivo, the loading dose was not designed to compensate for Fab-arm exchange-related affinity loss; the Fab-arm exchange phenomenon reduces effector function, not CGRP binding affinity, and is not the pharmacokinetic basis for the loading dose regimen.
Option B: Option B is incorrect because galcanezumab does not cross the blood-brain barrier at any dose — neither 240 mg nor 120 mg achieves clinically meaningful CNS concentrations, and the therapeutic mechanism is peripheral CGRP blockade rather than central TNC receptor blockade; no loading dose achieves BBB penetration sufficient for central preventive efficacy.
Option C: Option C is incorrect because galcanezumab does not bind plasma albumin with high affinity in a saturable manner that governs drug distribution; IgG antibodies distribute primarily in the intravascular and extracellular spaces and are not subject to the albumin saturation pharmacokinetics described; this mechanism does not correspond to the established pharmacokinetics of any approved anti-CGRP antibody.
Option D: Option D is incorrect because IgG4 antibodies have similar FcRn binding properties and half-lives to other IgG subclasses — approximately 27 to 31 days for galcanezumab, comparable to erenumab (IgG2) and fremanezumab (IgG2a); IgG4 does not have significantly reduced FcRn binding affinity that shortens its half-life compared to IgG1 or IgG2, and the loading dose was not designed to compensate for faster clearance.